GET THE APP
A Therapeutic Targeting Identification from Microarray Data and Quantitative Network Analysis | Abstract
AgiAl Publishing House

The Open Access Journal of Science and Technology

Abstract

About the Journal Abstracting and Indexing Aim and Scope Author Guidelines Article Processing Charges Articles in Process Contact Information Disclosure Policy and Publication Ethics Editorial Board Editorial Workflow Archive
Google Scholar citation report
Citations : 409

The Open Access Journal of Science and Technology received 409 citations as per Google Scholar report

Flyer image
Indexed In
  • Genamics JournalSeek
  • Directory of Open Access Journals
  • Pollution Abstracts
  • Publons
  • International committee of medical journals editors (ICMJE)
  • Google Scholar
  • Chemical Abstract
View More
Awards Nomination

A Therapeutic Targeting Identification from Microarray Data and Quantitative Network Analysis

Author(s): Hongliang Hu, Qinghua Zhang, Shen Li, Xiaona Zhang, Junsong Han, Huasheng Xiao,David Yan,Jie Zheng,and Biaoru Li

Personalizedtherapyis“therightdrugfortherightpatientattherighttime”.Herewereportedacaseofpersonalized therapyusinggeneexpressionsignature(GES)relateddrugdiscoverytotreatapatientwithdrug-resistantmetastasesfrombreasttumor.Methods:AftermRNAobtainedfrommetastaticlivertissuewasperformedbymicroarray,GESofgenomicprofileswere uncoveredbybioinformaticstoolandtargetingdrugsrelatedwithGESwereminedbydrug-bank.Severaltargeting-drugsapproved byFDAwereselectedtotreatthepatient.Results:1198geneswereuncoveredforthehigherexpressionbytwo-foldtocompare normalliverspecimensinwhich10ofminedgeneswereidentifiedasset-1GESformetastasisand16ofgeneswereuncovered as set-2 directly for primary breast tumor. Drug-bank platform were used to discover drugs for target set-1/2 genes. Eventually, medropxyoprogesterone (MPA) targeting set-I gene and doxorubicin targeting set-2 gene were selected for the patient because the two drugs have already been approved by FDA. After doxorubicin and MPA were administered, patient’s metastatic-tumor showedcompleteresponse.Conclusions:Wenotonlyanalyzegenomicexpressionprofilesbutalsodiscoversensitivecompounds fordrug-resistanttumor.WesuccessfullyselectdrugsapprovedbyFDAtotreatthepatient.

<

Share this article